Myovant Sciences Ltd represents values of innovation, integrity, and collaboration in the biopharmaceutical industry. With a commitment to advancing women's health and prostate cancer treatments, Myovant Sciences focuses on developing novel therapies that address critical unmet medical needs. The company's corporate philosophy revolves around scientific excellence, patient-centricity, and responsible business practices. By combining cutting-edge research with a passion for making a difference, Myovant Sciences strives to improve the lives of patients globally. As a leader in the field, Myovant Sciences Ltd continues to push boundaries and shape the future of healthcare.

Myovant Sciences Ltd is primarily present in multiple countries and regions around the world. The company has a global presence, with a focus on regions such as the United States, Europe, and Asia. Their innovative approach and commitment to improving healthcare have allowed them to expand their operations internationally, reaching patients and healthcare professionals in various markets. With their extensive reach, Myovant Sciences Ltd continues to make significant contributions to the field of medicine and positively impact the lives of individuals across different countries and regions.

Myovant Sciences Ltd has achieved several significant milestones. In 2018, the company announced positive Phase 3 clinical trial results for relugolix, its lead product candidate for the treatment of uterine fibroids and endometriosis-associated pain. These results demonstrated the drug's efficacy and safety in reducing menstrual blood loss and alleviating pain. In 2020, Myovant Sciences received FDA approval for relugolix in the treatment of advanced prostate cancer. This marked a major breakthrough as it became the first and only oral gonadotropin-releasing hormone receptor antagonist approved by the FDA for this indication. Myovant Sciences continues to innovate and develop novel therapies to address unmet medical needs.

Myovant Sciences Ltd is a biopharmaceutical company specializing in the development and commercialization of innovative therapies. Established in 2016, Myovant Sciences focuses on improving the lives of patients suffering from women's health and prostate cancer conditions. The company aims to address significant unmet medical needs through its proprietary product pipeline and strategic collaborations. Through their dedication to scientific advancement and patient-centric approach, Myovant Sciences aims to make a positive impact on the healthcare industry. With a strong focus on research and development, Myovant Sciences Ltd continues to strive towards bringing novel therapies to market to benefit patients worldwide.

Some of the main competitors of Myovant Sciences Ltd in the market include AbbVie Inc., TherapeuticsMD, and ObsEva SA.

Myovant Sciences Ltd is primarily active in the biotechnology and pharmaceutical industries.

Myovant Sciences Ltd is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for women's health and endocrine diseases. The company aims to address significant unmet medical needs with its cutting-edge research and drug development. Myovant Sciences utilizes strategic partnerships and collaborations to advance its pipeline of potential treatments. The company primarily focuses on areas such as uterine fibroids, endometriosis, and prostate cancer. By leveraging its expertise and research capabilities, Myovant Sciences is dedicated to improving the lives of patients and delivering value to its shareholders through its unique business model.

Myovant Sciences P/E suhe on −48,02.

Myovant Sciences KUV on 3,58.

AlleAktien kvaliteediskoor ettevõttele Myovant Sciences on 3/10.

oodatud Myovant Sciences käive on 701,44 mln. USD.

oodatud Myovant Sciences kasum on −52,23 mln. USD.

Myovant Sciences Ltd is a biopharmaceutical company based in London that focuses on developing high-quality therapeutics for women and men. The company's business model is based on research and development of treatments for various medical conditions such as cancer, endometriosis, and infertility. They offer both preclinical and clinical development programs, working closely with renowned research institutions and medical experts to develop innovative solutions for patients, particularly focusing on hormone treatments. Myovant's product portfolio includes several products and medications in various stages of development, with one of the main products being Relugolix, which has shown promise in clinical studies for the treatment of cancer (prostate cancer), endometriosis, and uterine fibroids. It aims to reduce the growth rate of cancer cells by inhibiting certain hormones, potentially halting or even reversing the progression of the disease. Another substance, RVT-601, is currently being developed primarily for the treatment of bladder problems in women. Myovant Sciences operates in different markets and has distribution partners in Europe, USA, and Asia. The company's goal is to establish itself as a leading company in the field of hormone therapy and transform the healthcare industry as a whole. It focuses on therapies that regulate hormone balance and support the body's natural functions, particularly benefiting patients with congenital or hormone-related conditions. Additionally, Myovant is involved in initiatives to empower women within society, partnering and campaigning for equality, awareness, and access to healthcare services for women under the brand MyoEmpower. To conclude, Myovant Sciences Ltd is a promising company specializing in the development of high-quality therapeutics for women and men. Their strategic focus on hormone therapy and collaboration with renowned research institutions position them as industry innovators.

Myovant Sciences maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Myovant Sciences jaoks arvutada või ettevõte ei maksa dividende välja.

Myovant Sciences ISIN on BMG637AM1024.

Myovant Sciences WKN on A2DFYA.

Myovant Sciences tähis on MYOV.

Viimase 12 kuu jooksul maksis Myovant Sciences dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Myovant Sciences tõenäoliselt dividendi summas 0 USD.

Myovant Sciences praegune dividenditootlus on .

Myovant Sciences maksab kvartaalset dividendi. See makstakse välja kuudel .

Myovant Sciences maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Myovant Sciences on liigitatud sektorisse 'Tervis'.

Viimase Myovant Sciences dividendide saamiseks 17.1.2025 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 17.1.2025.

Viimane dividendimakse toimus 17.1.2025.

Aastal 2024 maksis Myovant Sciences 0 USD dividende.

Myovant Sciences dividendid makstakse välja USD.